haloperidol has been researched along with 2,3-dioxo-6-nitro-7-sulfamoylbenzo(f)quinoxaline in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 2 (100.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Schmidt, WJ; Zadow, B | 1 |
Bittigau, P; Bosch, F; Dikranian, K; Ikonomidou, C; Miksa, M; Olney, JW; Stefovska, V; Tenkova, TI; Turski, L; Vöckler, J | 1 |
2 other study(ies) available for haloperidol and 2,3-dioxo-6-nitro-7-sulfamoylbenzo(f)quinoxaline
Article | Year |
---|---|
The AMPA antagonists NBQX and GYKI 52466 do not counteract neuroleptic-induced catalepsy.
Topics: Animals; Anti-Anxiety Agents; Antipsychotic Agents; Benzodiazepines; Catalepsy; Dizocilpine Maleate; Drug Interactions; Ergolines; Haloperidol; Levodopa; Male; Pilot Projects; Quinoxalines; Quinpirole; Rats; Rats, Sprague-Dawley; Receptors, AMPA | 1994 |
Blockade of NMDA receptors and apoptotic neurodegeneration in the developing brain.
Topics: Animals; Apoptosis; Brain; Calcium Channel Blockers; Dizocilpine Maleate; Dopamine Antagonists; Dose-Response Relationship, Drug; Excitatory Amino Acid Antagonists; Fetus; Haloperidol; Immunohistochemistry; In Situ Nick-End Labeling; Microscopy, Electron; Muscarinic Antagonists; Nerve Degeneration; Neurons; Quinoxalines; Rats; Receptors, N-Methyl-D-Aspartate; Scopolamine | 1999 |